文献速递心外重症与机械循环支持

主动脉内球囊反搏支持下成人的心脏移植等待名单生存率与其他Status 2、Status 1及依赖正性肌力药的Status 3患者的比较

Heart waitlist survival in adults with an intra-aortic balloon pump relative to other Status 2, Status 1, and inotrope Status 3 patients.
PubMed 文献 · J Heart Lung Transplant · 2022-10-18

基于美国器官共享联合网络的回顾性分析,纳入当前分配政策下所有成人Status 2心脏移植等待者3638例,其中1676例(46%)因主动脉内球囊反搏(IABP)列为Status 2。与IABP支持者相比,因室性心动过速/心室颤动(VT/VF)、右心室或双心室辅助装置配置或临时外科左心室辅助装置(LVAD)列为Status 2的患者等待名单死亡和失代偿风险更高;IABP支持者的风险与因大剂量正性肌力药列为Status 3者相似,且低于Status 1患者。

要点

  • 因VT/VF(HR 4.0,p < .001)、右心室或双心室辅助装置配置(HR 2.3,p = .002)或临时外科LVAD(HR 2.6,p = .003)列为Status 2者,等待名单死亡和失代偿风险高于IABP支持的Status 2患者。
  • IABP支持的Status 2患者等待名单死亡和失代偿风险与因大剂量正性肌力药列为Status 3者相似(HR 1.2,p = .27)。
  • IABP支持的Status 2患者等待名单死亡和失代偿风险低于Status 1患者(HR 0.7,p = .002)。

核心结论

  • 等待名单死亡率因Status 2准入标准不同而差异显著,因VT/VF、右心室或双心室辅助装置配置或临时外科LVAD列为Status 2者最高。
  • IABP支持的Status 2患者等待名单死亡风险处于最低之列,与因大剂量正性肌力药列为Status 3者相当。

研究设计与样本

  • 回顾性分析美国器官共享联合网络数据,纳入当前美国分配政策下所有成人Status 2心脏移植等待者,并纳入Status 1和因大剂量正性肌力药列为Status 3者作参考。
  • 共识别3638例Status 2等待者,其中1676例(46%)因IABP列为Status 2。
  • 采用病因别Cox生存模型,将死亡和等待名单失代偿建模为时变状态的函数。

主要发现

  • 与IABP支持的Status 2患者相比,因VT/VF列为Status 2者等待名单死亡和失代偿风险更高(HR 4.0,p < .001)。
  • 与IABP支持的Status 2患者相比,右心室或双心室辅助装置配置者风险更高(HR 2.3,p = .002),临时外科LVAD者风险更高(HR 2.6,p = .003)。
  • 其他Status 2亚组的死亡率与IABP支持的Status 2患者相当。
  • IABP支持的Status 2患者等待名单死亡和失代偿风险与因大剂量正性肌力药列为Status 3者相似(HR 1.2,p = .27)。
  • IABP支持的Status 2患者等待名单死亡和失代偿风险低于Status 1患者(HR 0.7,p = .002)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intra-aortic balloon pump (IABP) utilization has significantly outpaced other Status 2 eligibility criteria for heart transplant. The risk of waitlist mortality of IABP-supported patients relative to other Status 2 listed patients has not been described. METHODS: We performed a retrospective analysis of all adult patients listed Status 2 for heart transplantation under the current U.S. allocation policy, using data from the United Network for Organ Sharing. Patients listed status 1 and status 3 for high-dose inotropes were included for reference. Mortality and waitlist decompensation were modeled as a function of time-varying status in cause-specific Cox survival models. RESULTS: We identified 3638 Status 2 listings, of whom 1676 (46%) were Status 2 due to IABP. Relative to patients supported with IABP, status 2 patients with ventricular tachycardia/fibrillation [VT/VF] (HR 4.0, p < .001), right-or-biventricular assist device configurations (HR 2.3, p = .002), or temporary surgical left ventricular assist devices [LVAD] (HR 2.6, p = .003) had greater risk of waitlist mortality and decompensation. Other Status 2 subgroups had mortality comparable to IABP Status 2. Risk of waitlist mortality and decompensation for IABP Status 2 was similar to Status 3 patients listed for high-dose inotropes (HR 1.2, p = .27) and lower than Status 1 patients (HR 0.7, p = .002). CONCLUSIONS: Waitlist mortality varies significantly by Status 2 eligibility criteria and is highest among patients listed for VT/VF, right-or-biVAD configurations, or temporary surgical LVADs. IABP-supported patients were among those with the lowest Status 2 waitlist mortality risk and comparable to Status 3 inotrope-supported patients.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Hanff TC, Browne A, Dickey J, et al. Heart waitlist survival in adults with an intra-aortic balloon pump relative to other Status 2, Status 1, and inotrope Status 3 patients. J Heart Lung Transplant. 2022. PMID: 36369224. doi:10.1016/j.healun.2022.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。